Medtech firm 52 North Health and the University of Cambridge have been awarded £200,000 through the Innovate UK Knowledge Transfer Partnership (KTP), with the funding set to help the medtech firm translate its research into products.
52 North Health, which is based in the University of Cambridge’s Hauser Forum, is best known for its low-cost NeutroCheck device, which is used to test people at home for suspected neutropenic sepsis. The company recently raised £1 million in funding to help progress the development of the NeuroCheck device and its accompanying app.
This year, the company was also awarded the Tech for Good Award at the Cambridge Independent Science & Technology Awards 2022.
The award of funding through the KTP programme will primarily be used to fund the creation of a new 2.5 year role for an immunoassay scientist. This role will be used to develop and validate novel antibodies, which will help to create cost-effective rapid diagnostic solutions. Also included is a bespoke residential training programme.
University of Cambridge Department of Chemistry group leader Dr Pietro Sormanni commented: “From an academic standpoint, this partnership represents the unique opportunity to translate the fundamental research we carry out into clinical reality, with the potential to greatly improve the healthcare journey of many patients.”